These findings suggest that small molecule therapy by SHP2 inhibition acts as an immunotherapy, which may be especially useful in neurofibroma where traditional antibody-based immunotherapy and its associated toxicities may not be tolerable. This evidence concerns the gene PTPN11 and plexiform neurofibroma.